Navigation Links
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,,Its New Long Acting Drug For Erectile Dysfunction

All Endpoints Met - Up to 88% Efficacy

SEOUL, Korea, March 28, 2007 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that it has completed a 340 patient phase 2b "at-home" clinical study for udenafil, its new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in the U.S. was a randomized, double-blind, placebo controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. Following a 4-week non-drug baseline period, 340 men with ED of broad etiology and severity were randomized to one of four treatment groups: Placebo, udenafil 50mg, udenafil 100mg or udenafil 150mg. The drug treatment period was 12 weeks with evaluations every 4 weeks. The primary efficacy endpoints were the change in the International Index of Erectile Function (IIEF) Erectile Function Domain (EF) score from baseline to final visit; mean vaginal penetration success rates and mean intercourse completion rates calculated from the Sexual Encounter Profile (SEP) questions 2 and 3, respectively. The study had several secondary efficacy measurements including changes in scores from the other IIEF domains, scores from the remaining SEP questions, changes from baseline in the Patient Self-Assessment Questionnaire (PSAE) and the mean Global Assessment Score (GAQ).

All primary efficacy endpoints were statistically significant compared to placebo. The mean vaginal penetration success rates were 72% (50mg), 88% (100mg) and 82% (150mg) and significantly (p<0.001) higher compared to the 60% observed in the placebo group. The mean intercourse completion rates were 53% (50mg), 66% (100mg) and 69% (150mg) and significantly (p<0.001) higher compared to the 38% observed in the placebo group. Patients reporting improved erections after the 12-week course of therapy were 58% (50mg), 80% (100mg) and 73% (150mg) and signif
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/25/2009)...,, NEWYORK,Nov.25/PRNewswire/--Reportlinker.c...initscatalogue: ,, PainManagement-GlobalTrend...in-Management---Global-Trends.html ,, Widespre...mentclinics,andtheadventofnewdrugshaveacceleratedt...reformsandreimbursementstructurecontinuetoshapedem...
(Date:11/24/2009)...,, BETHESDA,Md.,Nov.24/PRNewswire-Asia/--Chin...leadingindependentAmericanproviderofWestern,health...a,today,announcedthattheCompanywillattendthe21stAn...obeheldDecember1-2,2009,atthe,NewYorkPalaceHotel. ...:30amETonTuesday,December1,2009,andholdone-on-one...
(Date:11/24/2009)...,, SANDIEGO,Nov.24/PRNewswire-FirstCall/--Ana...aythatitwillpresentatthe21stAnnualPiperJaffrayHeal...EST(6:00a.m.PST).TheconferenceisbeingheldatTheNewY...fExecutiveOfficerofAnadys,willprovideanoverviewofA...A773. ,, Thecorporatepresentationwillbesimultan...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Chindex International to Present at Piper Jaffray Health Care Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2MHPA Leading Association Representing Medicaid Health Plans Issues Statement on Proposed California SCHIP Elimination 47534 1MHPA Leading Association Representing Medicaid Health Plans Issues Statement on Proposed California SCHIP Elimination 47534 2IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 1IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 2IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 3IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 4IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 5Nuvilex Launches Video Marketing Campaign 47528 1Nuvilex Launches Video Marketing Campaign 47528 2Nuvilex Launches Video Marketing Campaign 47528 3
... Activity and Long-Term Tumor Re... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) to...l data,showing that Trubion,s TRU-016 has potent a...rm tumor eradication in a human tumor xenograft mo...sponses. TRU-016 is Trubion,s,proprietary CD37-tar...
...ential New Front-Line Treatment ...2 Genzyme Corp.,(Nasdaq: GENZ ) reported prelimi...se 2 study examining the safety and effectiveness ...eviously untreated, older adult,patients with acut...enefit,from conventional "7+3" anthracycline plus ...
Other Medicine Technology:Trubion Announces Presentation of Positive TRU-016 Data at ASCO 2Trubion Announces Presentation of Positive TRU-016 Data at ASCO 3Trubion Announces Presentation of Positive TRU-016 Data at ASCO 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8
(Date:11/25/2009)...ous discovery that grew out of a collaboration bet...ly offer hope to the nearly 10 million Americans w... Also known as hardening of the arteries, periphe...ory problem in which narrowed arteries reduce bloo... red flag for vascular disease, heart attack and s...
(Date:11/25/2009)...ready used to fight rheumatoid arthritis, could he... , WEDNESDAY, Nov. 25 (HealthDay News) -- A dru...d rheumatoid arthritis now also shows some promise...iabetes. , The drug, rituximab (Rituxan), helpe...n, even though the disease had destroyed some of t...
(Date:11/25/2009)...en plagued by neurological symptoms, study finds ...-- Neurological side effects are among the potenti...ular cancer who were treated with cisplatin-based ...y included 1,409 Norwegian men treated for unilate...ok part in a follow-up survey conducted from 1998 ...
(Date:11/25/2009)...GTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAmerica...hCareFraudActof2009,"S.2128,whichisdesignedtosubst...fraudinMedicare.ThebillwasintroducedbySen.GeorgeLe...provisionstheAmericanAssociationforHomecareoutline...tionproposedtoCongressinFebruary.Thoseprovisionsin...
(Date:11/25/2009)... to treat colorectal cancer also can reverse a rar...line therapy for the disease, researchers at Vande..., Mntrier,s disease causes thickening of the stom...ting, as well as anemia and swelling in the feet a...reased risk for gastric cancer. Previously, the on...
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2
...inska Institutet, our everyday environments are fu...ying degrees when inhaled. Particularly damaging t...rground system in Stockholm, Sweden. "Luckily... My results show that there is every reason to spe...
...ving a toll on the health of the children of the c....// Fast and junk food are the most favoured...ocket money in these joints rather than have a dec...fast foods is resulting in an increase in the inci...
...a tight spot, defending its position against the l...ompany’s best-selling schizophrenia drug, Zyprexa....health risks of the drug, which is being linked to...ence has surfaced, that the company has indeed kep...
...y gatherings to prepare for, the winter season can...pectations and the stresses of holiday events can ... depression is one of the most common illnesses fo...director of the Adult Outpatient Psychiatry Servic...
...ure (USDA) have spent two years ascertaining the p... body composition of infants. The instrument ...em, the size of an infant was tested suitably unde...is team undertook a study of 56 healthy infants, c...
...ation and Authorization of Chemicals, has shifted ...icals to the// manufacturers. The chemical c... safe chemicals for safety of their business. ...roved this legislation on the use of toxic chemica...
Other Medicine News:Health News:Underground Air - Associated With - DNA Damages 2Health News:Child Obesity and Diabetes - A Major Problem in India, 2Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 2Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 3
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: